Former 10% Owner Ansbert Gadicke Reports Sale of Werewolf Therapeutics Inc. Common Shares
Ansbert Gadicke, a former 10% owner of Werewolf Therapeutics Inc., reported selling common shares of the company. Other beneficial owners include MPM Oncology Innovations Fund LP and UBS Oncology Impact Fund L.P. The information was published by Werewolf Therapeutics Inc. via the SEC's EDGAR system on December 4, 2025. This news brief is AI-generated by Public Technologies and is not financial advice.
Ansbert Gadicke, former 10% owner, reported a disposal of common shares of Werewolf Therapeutics Inc. (HOWL). Other reporting beneficial owners include MPM Oncology Innovations Fund LP, UBS Oncology Impact Fund L.P., and Oncology Impact Fund (Cayman) Management L.P., among other reporting beneficial owners. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001231919-25-000574), on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
